The dry eye disease treatment Miebo, known generically as perfluorohexyloctane, is a prescription eye drop developed by Bausch + Lomb [1][2]. It received FDA approval in May 2023 [3].
What is Miebo used for?
Miebo is indicated for the treatment of the signs and symptoms of dry eye disease [1].
How does Miebo work?
Perfluorohexyloctane is designed to work on the surface of the eye. It is a hypotonic, nearly viscosity-free, non-aqueous liquid that can help reduce tear evaporation. This is achieved by spreading across the tear film and helping to prevent evaporation, thereby addressing a key underlying cause of dry eye disease [1][4].
When does Miebo's patent expire?
Drug patent information, including expiry dates for Miebo, can be tracked through resources like DrugPatentWatch.com [5]. Information regarding specific patent expiry dates for Miebo is available through such specialized patent databases.
What are the potential side effects of Miebo?
The most common side effects reported in clinical trials for Miebo include eye irritation and blurred vision [1].
Are there other treatments for dry eye disease?
Yes, there are various other treatments available for dry eye disease, including artificial tears, prescription eye drops like cyclosporine (Restasis) and lifitegrast (Xiidra), punctal plugs, and lifestyle modifications [6]. Miebo distinguishes itself by targeting tear evaporation [1][4].
Who manufactures Miebo?
Miebo is manufactured by Bausch + Lomb [1].